Stay updated on Tirzepatide in HFpEF & Obesity Clinical Trial
Sign up to get notified when there's something new on the Tirzepatide in HFpEF & Obesity Clinical Trial page.

Latest updates to the Tirzepatide in HFpEF & Obesity Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference2%

- Check28 days agoChange DetectedThe page now announces Revision: v3.1.0 and removes four drug-safety related topics, indicating content reorganization and scope narrowing.SummaryDifference0.2%

- Check43 days agoChange DetectedAdded the new Revision: v3.0.2, replacing v3.0.1. The Back to Top element has been removed.SummaryDifference0.1%

- Check50 days agoChange DetectedThe web page has been updated to version 3.0.1, which includes a new study on the effects of Tirzepatide in patients with heart failure and type 2 diabetes, while the previous version 3.0.0 has been removed.SummaryDifference2%

- Check57 days agoChange DetectedThe web page has added significant new content related to the SUMMIT trial, including multiple publications and detailed location information for various regions, while also removing some previously listed locations and terms related to heart failure and cardiovascular diseases.SummaryDifference23%

- Check64 days agoChange DetectedThe web page has been updated to include new results and metrics related to heart failure outcomes, including specific measurements and assessments of participant health status, while some previous metrics and reporting dates have been removed.SummaryDifference27%

Stay in the know with updates to Tirzepatide in HFpEF & Obesity Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tirzepatide in HFpEF & Obesity Clinical Trial page.